GlassScriptPhysician profile
Fatima T Mohiuddin
NPI 1578674834
$522.85
in general payments reported to CMS, 2019-2025
15 companies · $15.27 in 2025
The $15.27 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $31.51 · 2023: $15.27 · 2024: $32.57 · 2025: $15.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $45.81 · Food and Beverage: $17.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $45.81 |
| Food and Beverage | $17.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $117.10 | 2019 | |
| Pfizer INC. | $114.84 | 2019-2025 | |
| Genzyme Corporation | $40.97 | 2019 | |
| Novo Nordisk INC | $38.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.80 | 2019 | |
| Checkpoint Surgical, INC | $29.15 | 2019 | |
| Alk-Abello, INC | $23.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.71 | 2019 | |
| Csl Behring | $17.30 | 2024 | Hizentra |
| Horizon Therapeutics Plc | $16.53 | 2020 | |
| Mylan Specialty L.P. | $16.43 | 2019 | |
| Amgen INC. | $15.59 | 2019 | |
| Pharming Healthcare, INC. | $14.98 | 2020 | |
| Merck Sharp & Dohme LLC | $12.91 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.